SEER
Biotechnology · Healthcare
CEO, Board Member
2017-01-01–present
Board Member
Seer, Inc. (SEER)Equibles does not estimate personal net worth.
Get an email with a short summary when Seer, Inc. publishes a filing, an earnings call transcript or a press release.
Get SEER alertsOmid Farokhzad is recorded as Board Member at Seer, Inc. (SEER) since January 1, 2017 and CEO at Seer, Inc. (SEER). The newest filing on record that lists Omid Farokhzad as CEO and Board Member at Seer, Inc. (SEER) is dated May 28, 2025. The proxy statement of Seer, Inc. reports total compensation of $3,549,950 for Omid Farokhzad in fiscal 2024, including a base salary of $619,208. Disclosed compensation is on record for 6 fiscal years. Omid Farokhzad has spoken on 23 earnings calls across 1 company, most recently for Seer, Inc. on August 11, 2026. Seer, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Seer, Inc. includes Charles Endweiss (CFO and Chief Accounting Officer), Elona Kogan (General Counsel), David Hallal (Board Member) and 7 others.
“I want to begin by acknowledging the ongoing efforts of the entire SEER team, whose daily contributions propel us towards a future where plodinomics can deliver a revolutionary impact for patients around the world.”
“At SEER, we're making significant progress on our innovation roadmap, commercial position, and strategic objectives as we start the year. We have said that our progress may not be linear quarter to quarter, but my conviction in SEER, the impact of our technology, and the market we're building has never been stronger.”
“I will begin our call today by providing updates on our business, and I will then turn the call over to David to provide more detail on our financial results for the fourth quarter and full year 2025, as well as our outlook for 2026.”
“I will begin our call today by providing updates on our business, and I will then turn the call over to David to provide more detail on our financial results for the third quarter of 2025 as well as our outlook for the full year.”
“I will begin our call today by providing updates on our business, and I will then turn the call over to David to provide more details on our financial results for the second quarter of 2025 as well as our outlook for the full year.”
2017-01-01–present
Last confirmed May 28, 2025
Start not stated–present
Last confirmed May 28, 2025
SEER
Biotechnology · Healthcare
CEO, Board Member
2017-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Seer, Inc. (SEER) | Chief Executive Officer | $619,208 | $3,549,950 |
| 2023 | Seer, Inc. (SEER) | Chief Executive Officer | $596,459 | $5,197,331 |
| 2022 | Seer, Inc. (SEER) | Chief Executive Officer | $568,375 | $6,736,092 |
| 2021 | Seer, Inc. (SEER) | Chief Executive Officer | $527,262 | $9,429,610 |
| 2020 | Seer, Inc. (SEER) | Chief Executive Officer | $434,448 | $10,476,186 |
| 2019 | Seer, Inc. (SEER) | Chief Executive Officer | $421,011 | $751,123 |